Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis

Author(s):
Montemurro, M.; Gelderblom, H.; Bitz, U.; Schutte, J.; Blay, J.Y.; Joensuu, H.; Trent, J.; Bauer, S.; Rutkowski, P.; Duffaud, F.; Pink, D.
Published
2013
Publication type
Article / Letter to editor
Gastrointestinal stromal tumourGISTSorafenibNilotinibSunitinibImatinibTyrosine kinase inhibitorRelapseSalvageProgression
Date issued
2013-03-31
Language
English
Is part of
European Journal of Cancer (2013), Vol. 49, no. 5, p. 1027-1031
hdl
1887/100095
doi
10.1016/j.ejca.2012.10.009